因塞特医疗宣布,其关键临床研究取得积极顶线数据,评估Tafasitamab(商品名Monjuvi®/Minjuvi®)作为弥漫性大B细胞淋巴瘤(DLBCL)一线治疗方案的效果。该结果标志着该药物在早期治疗应用中的重要进展。
因塞特医疗宣布,其关键临床研究取得积极顶线数据,评估Tafasitamab(商品名Monjuvi®/Minjuvi®)作为弥漫性大B细胞淋巴瘤(DLBCL)一线治疗方案的效果。该结果标志着该药物在早期治疗应用中的重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.